* Affymetrix Inc., of Santa Clara, Calif., and Rosetta Inpharmatics Inc., of Kirkland, Wash., entered into a DNA array internal-use license agreement. Under the terms of the non-exclusive, three-year deal, Affymetrix has granted Rosetta a license to certain of its patents, permitting the company to make and use mechanically spotted and ink-jet synthesized DNA arrays for internal and collaborative gene expression monitoring research initiatives. Financial terms were not disclosed.
* Maxim Pharmaceuticals Inc., of San Diego, began a Phase II trial of Maxamine Therapy in patients with advanced renal cell carcinoma. The trial is based in Sweden, Denmark and the U.K. About 40 patients are expected to be enrolled and treated for up to nine months with Maxamine, a natural cytokine Interferon Alfanative and interleukin-2, developed by BioNative AB, of Umea, Sweden.
* Medarex Inc., of Annandale, N.J., received a $7.5 million milestone payment from Xenotech LP, a joint-venture partnership among Cell Genesys Inc., of Foster City, Calif.; Abgenix Inc., of Fremont, Calif.; and Japan Tobacco Inc., of Tokyo. The payment was triggered by the issuance of a patent on Medarex's HuMAb-Mouse technology.
* MGI Pharma Inc., of Minneapolis, began enrolling patients in a Phase II clinical study with MGI 114 to treat ovarian cancer. Patients are women with advanced cancer who did not respond or are not responding any longer to a chemotherapy regimen that includes paclitaxel and platinum-based agents. MGI 114 is the lead compound in a family of cytotoxic agents called acylfulvenes.
* Myriad Genetics Inc., of Salt Lake City, said Bayer Corp., of Leverkusen, Germany, has extended the companies' five-year collaboration for genes related to asthma, osteoporosis and obesity until 2002. The deal is one of two between Myriad and Bayer. Extending it for two years adds $6.2 million in committed research payments and up to $6 million more in potential milestone payments. (See BioWorld Today, Sept. 13, 1995, p. 1.)
* OraVax Inc., of Cambridge, Mass., filed for an investigational new drug application for a clostridium difficile (C. difficile) taxoid vaccine. The Phase I trial is scheduled to be conducted early next year at the Center for Vaccine Development at the University of Maryland. Baltimore. The company is developing two products for the prevention and treatment of C. difficile colitis. C. difficile is a spore-forming bacterium responsible for diseases ranging from diarrhea to life-threatening colitis, and is common in hospitalized elderly patients following treatment with broad-spectrum antibiotics.
* Pangea Systems Inc., of Oakland, Calif., said the Chinese National Human Genome Center at Shanghai has licensed Pangea's bioinformatics software, including its GeneWorld application; the information management environment PULSE; and scientific computational tools for use in genomics and target validation efforts.